Uriviga S Tablet contains Tamsulosin 400mcg + Solifenacin 6mg, a dual-action therapy for effective management of urinary disorders, including bladder outlet obstruction and overactive bladder. Tamsulosin relaxes the urinary tract muscles for improved flow, while Solifenacin reduces bladder overactivity, ensuring comprehensive symptom control and patient comfort.
This tablet is highly trusted by prescribers due to its consistent efficacy and tolerability, creating steady demand. Patients benefit from improved urinary function, reduced frequency, and relief from urinary urgency, enhancing treatment adherence.
For franchise partners, Uriviga S Tablet represents a high-demand urology therapy product with strong market acceptance. Its proven clinical performance and prescriber confidence make it a profitable addition to urology portfolios, supporting business growth and customer loyalty.
With its combination of urinary relief and bladder health support, Uriviga S Tablet offers sustainable sales potential, making it an ideal choice for partners serving the urology and urinary care market.